Abdominal visceral fat, particularly mesenteric fat, is causally linked to the development and progression of type 2 diabetes and Crohn's disease. This pathological fat depot is also strongly associated with heart failure, obstructive sleep apnea, and chronic kidney disease, positioning mesenteric fat as a central, disease-modifying target rather than a passive byproduct of obesity.
Adinova Medical is building the first Cryolipolysis platform to selectively target this fat and treat disease at its root cause.
How Cryolipolysis Works?
Fat cells are uniquely sensitive to cold temperatures, which allows for selective removal without collateral damage. Adinova's proprietary laparoscopic cryolipolysis approach, specifically targets mesenteric fat otherwise cannot be reached by any other means. Once cooled, these fat cells crystallize and naturally undergo programmed cell death, resulting in steady, controlled fat reduction.
The Adinova Cryolipolysis Procedure
- Minimally invasive laparoscopic procedure to target and kill visceral mesenteric fat.
- Dual-balloon cooling technology to deliver controlled cryotherapy directly to the mesenteric fat while sparing surrounding tissues.
- The platform offers a novel therapeutic approach for conditions like Type 2 diabetes, Crohn's disease and metabolic dysfunction.
- Clinical stage: first 5 patients treated with significant, durable, mesenteric fat reductions.
